









市场行情
/
股票
/
nasdaq-kros
/

Keros Therapeutics Inc

KROS

21.030USD

-0.330-1.54%

收盘 12/26, 16:00（美东）报价延迟15分钟

854.49M总市值

13.21市盈率 TTM



Keros Therapeutics Inc

21.030

-0.330-1.54%

概览公司财务分析

概览

公司

财务

分析

关于 Keros Therapeutics Inc 公司

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Keros Therapeutics Inc简介



公司代码KROS

公司名称Keros Therapeutics Inc

上市日期Apr 08, 2020

CEOSeehra (Jasbir)

员工数量169

证券类型Ordinary Share

年结日Apr 08

公司地址1050 Waltham Street, Suite 302

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02421

电话16173146297

网址https://www.kerostx.com/

公司代码KROS

上市日期Apr 08, 2020

CEOSeehra (Jasbir)

Keros Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Jasbir Seehra, Ph.D.

President, Chief Executive Officer, Director

392.72K

+29.94%

Mr. Julius Knowles

Independent Director

6.44K

+440.81%

Mr. Jean-Jacques Bienaime ,

Independent Chairman of the Board

5.45K

+2625.00%

Dr. Carl L. Gordon, Ph.D.

Independent Director

5.25K

Mr. Nima Farzan

Independent Director

5.25K

Dr. Mary Ann Gray, Ph.D.

Independent Director

5.25K

Mr. Justin Frantz

Head of Investor Relations

Mr. Keith C. Regnante

Chief Financial Officer

-100.00%

Dr. Alpna Hansraj Seth, Ph.D.

Independent Director

Dr. Lorena Lerner, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Dr. Jasbir Seehra, Ph.D.

President, Chief Executive Officer, Director

392.72K

+29.94%

Mr. Julius Knowles

Independent Director

6.44K

+440.81%

Mr. Jean-Jacques Bienaime ,

Independent Chairman of the Board

5.45K

+2625.00%

Dr. Carl L. Gordon, Ph.D.

Independent Director

5.25K

Mr. Nima Farzan

Independent Director

5.25K

Dr. Mary Ann Gray, Ph.D.

Independent Director

5.25K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月20日周四

持股股东

股东类型

持股股东

占比

Madison Avenue Partners LP

8.89%

The Vanguard Group, Inc.

8.89%

Tang Capital Management, LLC

7.94%

BlackRock Institutional Trust Company, N.A.

7.73%

Western Standard, LLC

7.19%

其他

59.37%

持股股东

占比

Madison Avenue Partners LP

8.89%

The Vanguard Group, Inc.

8.89%

Tang Capital Management, LLC

7.94%

BlackRock Institutional Trust Company, N.A.

7.73%

Western Standard, LLC

7.19%

其他

59.37%

股东类型

持股股东

占比

Hedge Fund

44.98%

Investment Advisor

28.60%

Investment Advisor/Hedge Fund

23.28%

Research Firm

4.64%

Venture Capital

2.82%

Private Equity

2.64%

Corporation

1.89%

Individual Investor

1.79%

Pension Fund

1.13%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

385

41.03M

124.11%

-17.81M

2025Q2

392

46.16M

114.02%

-7.54M

2025Q1

394

39.41M

98.81%

-8.43M

2024Q4

366

43.10M

106.25%

-873.01K

2024Q3

351

43.05M

114.83%

+404.61K

2024Q2

337

39.69M

109.09%

-4.15M

2024Q1

332

39.81M

110.03%

+1.08M

2023Q4

310

34.40M

109.87%

-229.62K

2023Q3

303

31.04M

104.70%

-2.97M

2023Q2

305

30.88M

104.58%

-2.59M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Madison Avenue Partners LP

2.69M

6.63%

+77.06K

+2.95%

Jun 30, 2025

The Vanguard Group, Inc.

2.62M

6.45%

+53.89K

+2.10%

Jun 30, 2025

Tang Capital Management, LLC

1.42M

3.49%

+318.98K

+29.00%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.39M

5.88%

-118.03K

-4.71%

Jun 30, 2025

Western Standard, LLC

1.53M

3.78%

+1.40M

+1037.68%

Jun 30, 2025

D. E. Shaw & Co., L.P.

1.30M

3.19%

+34.25K

+2.71%

Jun 30, 2025

State Street Investment Management (US)

1.38M

3.41%

+81.72K

+6.27%

Jun 30, 2025

Nantahala Capital Management, LLC

1.62M

3.99%

+113.90K

+7.56%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.76%

ALPS Medical Breakthroughs ETF

0.26%

State Street SPDR S&P Biotech ETF

0.21%

Federated Hermes MDT Small Cap Core ETF

0.12%

Direxion Daily S&P Biotech Bull 3X Shares

0.1%

ProShares Ultra Nasdaq Biotechnology

0.09%

WisdomTree US SmallCap Quality Growth Fund

0.07%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

iShares Biotechnology ETF

0.05%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.76%

ALPS Medical Breakthroughs ETF

占比0.26%

State Street SPDR S&P Biotech ETF

占比0.21%

Federated Hermes MDT Small Cap Core ETF

占比0.12%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.1%

ProShares Ultra Nasdaq Biotechnology

占比0.09%

WisdomTree US SmallCap Quality Growth Fund

占比0.07%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.06%

Invesco Nasdaq Biotechnology ETF

占比0.06%

iShares Biotechnology ETF

占比0.05%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Keros Therapeutics Inc的前五大股东是谁？



Keros Therapeutics Inc 的前五大股东如下：
Madison Avenue Partners LP持有股份：2.69M，占总股份比例：6.63%。
The Vanguard Group, Inc.持有股份：2.62M，占总股份比例：6.45%。
Tang Capital Management, LLC持有股份：1.42M，占总股份比例：3.49%。
BlackRock Institutional Trust Company, N.A.持有股份：2.39M，占总股份比例：5.88%。
Western Standard, LLC持有股份：1.53M，占总股份比例：3.78%。